Silence Therapeutics presents additional Phase 1 data highlighting Divesiran

Silence Therapeutics (SLN) “presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera at the European Hematology Association 2025 Annual Meeting in Milan, Italy. The Phase 1 portion of SANRECO was a 34-week, open-label study evaluating divesiran administered subcutaneously every 6 weeks for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria included a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five in the last year prior to screening. Patients were allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 study, both well-controlled patients – defined as those with HCT levels at 45% or less – as well as those with HCT levels greater than 45% at baseline on current standard of care treatment were enrolled.”